Immune cell therapy targeting EGFRvIII for recurrent glioblastoma
Part of Cancer clinical trials.
This trial tests a new treatment for recurrent glioblastoma, a type of brain cancer that has returned. The treatment uses your own immune cells, modified in a lab to find and attack a specific marker on the tumor, called EGFRvIII. It might help because it targets the cancer cells directly and may slow or stop their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your brain tumor must have come back or grown after standard treatment, and it must have a specific marker called EGFRvIII (even after previous targeted treatment).
- You must be able to do most daily activities (score of 60 or more on a scale called KPS, and a low score on another scale called ECOG).
- Your heart, lungs, liver, and kidneys must be working well enough, and you must not have active hepatitis B or C, HIV, or syphilis.
- You must stop taking high-dose steroids at least 2 weeks before starting, and wait at least 8 weeks after radiation, 6 weeks after certain chemo, and 14 days after other chemo.
- If you are in the injection group, you must be able to have a small device (Ommaya reservoir) placed in your head.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
This Phase 1 trial tests BRiTE, a custom immune “match” therapy designed to attack glioblastoma cells that have a specific EGFRvIII change. It’s for adults with newly diagnosed or recurring grade 4 glioblastoma, aiming to see safety and whether the treatment can shrink or control tumors.
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new treatment called CAR-T cell therapy for people whose glioblastoma (a type of brain tumor) has come back or not responded to standard care. The treatment uses your own immune cells (T cells) that are specially modified to attack tumor cells that show a marker called CD276.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.